Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination

Ryan C. Neal, Peter H. Jones

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Cardiovascular (CV) disease remains the number 1 cause of death in the USA. Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease (CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors, such as hypertension, diabetes, and dyslipidemia. The recent update to the National Cholesterol Education Program (NCEP) guidelines have recommended lower low-density lipoprotein cholesterol (LDL-C) goals in high-risk patients. Based on the new targets for LDL-C, clinicians will need more efficacious lipid-lowering therapies. One of these newer therapies is the combination of ezetimibe and simvastatin. This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalVascular Health and Risk Management
Issue number1
StatePublished - 2006


  • Combination lipid treatment
  • Ezetimibe
  • Statin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination'. Together they form a unique fingerprint.

Cite this